Centogene N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CNTG research report →
Range $2.5 – $2.5
Price Chart
About the company
Centogene N. V. , along with its affiliates, operates globally with a primary focus on rare diseases.
- CEO
- Kim Stratton
- IPO
- 2019
- Employees
- 384
- HQ
- Rostock, DE
Get TickerSpark's AI analysis on CNTG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.42M
- P/E
- -0.23
- PEG
- -0.01
- P/S
- 0.18
- P/B
- -0.33
- EV/EBITDA
- -3.64
- Div Yield
- 0.00%
- Gross Margin
- 35.54%
- Op Margin
- -61.11%
- Net Margin
- -73.21%
- ROE
- 397.65%
- ROIC
- -47.95%
Latest fiscal year · YoY change
- Revenue
- $48.54M+2.2%
- Gross Profit
- $17.25M-13.4%
- Op Income
- $-29,659,000
- Net Income
- $-35,532,000-11.6%
- EPS
- $-1.27-14.4%
- OCF Growth
- -19.9%
- FCF Growth
- -19.1%
- 52W High
- $0.43
- 52W Low
- $0.33
- 50D MA
- $0.16
- 200D MA
- $0.26
- Beta
- -0.67
- RSI (14)
- 84
- Avg Volume
- 431.57K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
CENTOGENE ended 2021 with strong core-business recovery and better diagnostics momentum, while still carrying a heavy COVID-testing mix that management expects to phase out in early 2022.· March 30, 2022
- Full-year 2021 revenue rose over 48% to €190 million, mainly from €146.4 million of COVID-19 testing revenue.
- Core business revenue grew 11% to €43.5 million, with Q4 core revenue up 34% year over year.
- Diagnostics recovered to €27.9 million for the year, up 26%, and Q4 diagnostics revenue was €7.5 million, back to pre-pandemic levels.
- Pharma revenue was €15.6 million for 2021, down 8% year over year, but Q4 pharma revenue grew 40% to €6.5 million.
- Management guided 2022 core business revenue growth of 15% to 20%, with total revenue guidance of €68 million to €70 million as COVID testing winds down.
Revenue for full-year 2021 increased over 48% to €190 million from €128.4 million in 2020. Core business revenue rose 11% to €43.5 million, and Q4 core business revenue grew 34% year over year. Diagnostics revenue was €27.9 million in 2021, up 26%, with Q4 diagnostics revenue at €7.5 million, up 30%; pharma revenue was €15.6 million in 2021, down 8%, with Q4 pharma revenue up 40% to €6.5 million. Overall gross margin was 15% in 2021 versus 35% in 2020, while core business gross margin improved to 34% from 14%. Full-year adjusted EBITDA contribution from the COVID segment was €20.7 million, total segment adjusted EBITDA was €29.5 million, and core business segment adjusted EBITDA was €8.9 million versus €3.8 million in 2020. Management guided 2022 core business revenue growth of 15% to 20%, COVID testing revenue of about €18 million, all in Q1, and total 2022 revenue of €68 million to €70 million.
Kim Stratton framed the year as a transition toward a more focused rare-disease platform, emphasizing three strategic pillars: biopharma partnerships, the CENTOGENE Bio/Databank, and diagnostics. She highlighted improving execution, a stronger partnership pipeline, and several recent collaborations including Pfizer, Alector, Agios, Twist, and Insilico. Her tone was constructive and optimistic, but she also noted that pharma recovery will take time and that Q1 2022 should be relatively flat to modestly growing before momentum improves in the second half.
Miguel Coego Rios focused on the financial reset after a COVID-driven year, citing full-year revenue of €190 million, cash and cash equivalents of €17.8 million at December 31, 2021, and lease liabilities of approximately €19 million. He said operating cash flow used was €21.7 million, investing cash flow used was €5.4 million, and financing cash flow used was €3.2 million. He also pointed to a sharp improvement in core-business profitability, with core business gross margin at 34% versus 14% last year and core-business adjusted EBITDA at €8.9 million versus €3.8 million, while saying corporate costs should decline in 2022 as restructuring takes hold and that management will prioritize expense discipline and resource allocation.
Analysts focused on cash burn, runway, sample growth in the Bio/Databank, growth assumptions for Diagnostics versus Pharma, margin outlook, and whether recent contract-value gains in Pharma can continue. Management said it did not provide a specific cash-burn guide, but the financing was intended to fund the company for a couple of years and should extend runway; it also said more detail would come in future communications. On the Bio/Databank, Bettina Goerner said the company added 94,000 individuals in 2021 and sees itself on track toward the 1 million patient goal. Management also said Diagnostics should grow above the market rate of about 11%, Pharma should recover more slowly and become a larger share of the core business over time, and Q1 core performance should be flat to modestly up before strengthening in the second half.
The bull case from this call is that the core business is clearly recovering: Diagnostics has returned to pre-pandemic revenue levels, Q4 core revenue grew 34%, and core-business gross margin improved sharply to 34%. Management also pointed to a richer partnership pipeline, a growing Bio/Databank, and new or expanded collaborations with Pfizer, Agios, Alector, Twist, and Insilico as evidence that the platform is gaining strategic traction.
The main risks are that 2021 was still heavily dependent on COVID-testing revenue, which is being phased out, and that total revenue guidance for 2022 drops to €68 million to €70 million as that business disappears. Pharma remains below prior-year revenue levels, Q1 is expected to be only flat to modestly up in core business, and management acknowledged it has not yet provided a specific cash-burn guide, despite reporting just €17.8 million of cash at year-end 2021 before the later financing.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 40.6%
- Shares Outstanding
- 28.98M
- Float Shares
- 11.78M
of shares held by institutions
11 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 18.30K | 0 |
Held by 1 ETFs
Biggest fund positions in CNTG by dollar value.
Our CNTG coverage
Recent articles, reports, and earnings notes.
No research on CNTG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CNTG report →CENTOGENE Closes Strategic Transaction with Private Equity Group Charme Capital Partners
globenewswire.com · Mar 12
CENTOGENE Announces Voting Results of Extraordinary General Meeting
globenewswire.com · Dec 4
CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners
globenewswire.com · Nov 13
CENTOGENE Data on Novel Genetic Risk Factor for Parkinson's Disease in The Lancet Neurology
globenewswire.com · Sep 25
CENTOGENE Receives Delisting Notice From Nasdaq
globenewswire.com · Aug 7
CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson's Disease Cases Are Linked to Genetic Factors
globenewswire.com · Aug 1
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
globenewswire.com · Jun 20
CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting
globenewswire.com · May 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.